Establishing a predictive model for tumor mutation burden status based on CT radiomics and clinical features of non-small cell lung cancer patients

BACKGROUND: Tumor mutation burden (TMB) is one of the biomarkers for efficacy of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). Due to the potential of radiomic signatures to identify microscopic genetic and molecular differences, thus radiomics is considered a suitable t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jihua, Shi, Wenjia, Yang, Zhen, Yu, Hang, Wang, Miaoyu, Wei, Yuanhui, Wen, Juyi, Zheng, Wei, Zhang, Peng, Zhao, Wei, Chen, Liang’an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183386/
https://www.ncbi.nlm.nih.gov/pubmed/37197623
http://dx.doi.org/10.21037/tlcr-23-171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183386/
https://www.ncbi.nlm.nih.gov/pubmed/37197623
http://dx.doi.org/10.21037/tlcr-23-171

Ejemplares similares